Spain Antibody Drug Conjugates Contract Manufacturing Market Size & Outlook
Related Markets
Spain antibody drug conjugates contract manufacturing market highlights
- The Spain antibody drug conjugates contract manufacturing market generated a revenue of USD 106.4 million in 2024 and is expected to reach USD 190.9 million by 2030.
- The Spain market is expected to grow at a CAGR of 10.3% from 2025 to 2030.
- In terms of segment, myeloma was the largest revenue generating condition in 2024.
- Lymphoma is the most lucrative condition segment registering the fastest growth during the forecast period.
Antibody drug conjugates contract manufacturing market data book summary
| Market revenue in 2024 | USD 106.4 million |
| Market revenue in 2030 | USD 190.9 million |
| Growth rate | 10.3% (CAGR from 2025 to 2030) |
| Largest segment | Myeloma |
| Fastest growing segment | Lymphoma |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Myeloma, Lymphoma, Breast Cancer |
| Key market players worldwide | Sterling Check Corp, Recipharm, Lonza Group Ltd, Catalent Inc, Sartorius AG, WuXi Biologics (Cayman) Inc, Samsung BioLogics, Piramal Healthcare, AbbVie Inc, Merck KGaA |
Other key industry trends
- In terms of revenue, Spain accounted for 1.2% of the global antibody drug conjugates contract manufacturing market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany antibody drug conjugates contract manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 998.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Contract Manufacturing Market Scope
Antibody Drug Conjugates Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Piramal Healthcare | View profile | 5001-10000 | Mumbai, Maharashtra, India, Asia | http://www.piramalpharmasolutions.com |
| Sterling Check Corp | View profile | 5700 | 6150 Oak Tree Boulevard, Suite 490, Independence, OH, United States, 44131 | https://www.sterlingcheck.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | https://www.samsungbiologics.com/ |
| Recipharm | View profile | 1001-5000 | Jordbro, Stockholms Lan, Sweden, Europe | http://www.recipharm.com |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| WuXi Biologics (Cayman) Inc | View profile | 12740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | https://www.wuxibiologics.com |
| Sartorius AG | View profile | 14338 | Otto-Brenner-Strasse 20, Gottingen, NI, Germany, 37079 | https://www.sartorius.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
Spain antibody drug conjugates contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antibody drug conjugates contract manufacturing market will help companies and investors design strategic landscapes.
Myeloma was the largest segment with a revenue share of 54.61% in 2024. Horizon Databook has segmented the Spain antibody drug conjugates contract manufacturing market based on myeloma, lymphoma, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Spain has a high incidence of cancer; this is primarily due to the rapidly aging population. The Spanish Statistics Institute states that over 47 million people living in Spain are above the age of 65. The International Agency for Research on Cancer states that there were 282,000 cases of cancer in 2020, and by 2030, the incidence is expected to grow to 330,000.
Thus, the Spanish Ministry of Health, along with 10 other countries, signed the Valletta Declaration to jointly negotiate the price of expensive drugs, including advanced cancer drugs. This is expected to improve the adoption of antibody drug conjugates in Spain, thus boosting the demand for antibody-drug conjugates contract manufacturing in the country.
In 2019, the ESMO Congress was held in Spain, and Iksuda Therapeutics presented data on ADC, IKS01, at the event. Iksuda Therapeutics stated that IKS01 showed significant anti-tumor efficacy in pre-clinical models for ovarian and lung tumors.
Reasons to subscribe to Spain antibody drug conjugates contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Spain antibody drug conjugates contract manufacturing market databook
-
Our clientele includes a mix of antibody drug conjugates contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain antibody drug conjugates contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Spain antibody drug conjugates contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Spain antibody drug conjugates contract manufacturing market size, by condition, 2018-2030 (US$M)
Spain Antibody Drug Conjugates Contract Manufacturing Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
